TOKIWA-Bio is a gene-cell therapy and regenerative medicine product development company which has developed Stealth RNA Vector(SRV) an innovative technology of gene expression system. The SRV is the world-first RNA vector stabilized in cytoplasm and capable to install at least 10 genes on single vector.
TOKIWA-BioAnnounces Closing of Financing
November 14th, 2017
TOKIWA-Bio Inc., which is developed gene therapy and regenerative medicine, announced that it secured a new capital of 330 million yen through third-party allotment of shares allocated to operating companies and venture capital. TOKIWA - Bio Inc. plans to utilize financing to accelerate the development of multiple programs based on Stealth RNA Vector, which is its own platform technology.